glp-1 drugs manufacturers 2.0: Where the Next Wave of Value Will Be Created The Biggest Winner of GLP-1

Description

HOW TO OBTAIN WEGOVY (SEMAGLUTIDE) or Zepbound (trizepatide Wegovy (semaglutide) has become a first line therapy for chronic weight management , and now Zepbound has followed for adults with obesity or who are overweight with a BMI of 27 and have at least one weight-related comorbidity (such as type 2 diabetes, high blood pressure, or high cholesterol)

In general, I think its a good thing that there are new tools available for patients with obesity, which increases the risk of heart disease, diabetes, many forms of cancer and early death

Moreover, emerging therapeutic agents are under investigation

GLP-1RAs have been investigated for long-term use to achieve sustained WL effects [49, 61,62,63]

Front Endocrinol (Lausanne) 14:1240263 [DOI] [PMC free article] [PubMed] [Google Scholar] 17.Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fernandez Lando L, Bray R, Linge J et al (2025) Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial